TABLE 1.
Details of the included studies.
| Author | Year | Sample size | Age, mean ± SD | Male, No. (%) | Country | Follow-up duration | Tacrolimus dose (mg/d) | Blood trough level (ng/mL) | Outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before conversion | After conversion | Before conversion | After conversion | ||||||||
| Gaber et al. (2013) | 2013 | 47 | 45.6 ± NA | 32 (68.1) | America | 3 weeks | NA | NA | NA | NA | eGFR |
| Abedini et al. (2018) | 2018 | 91 | 47.7 ± 14.3 | 58 (63.7) | Norway | 48 weeks | 4.4 ± 2.5 | 4.4 ± 2.4 | 6.0 ± 1.4 | 5.5 ± 1.8 | eGFR |
| Rubik et al. (2019) | 2019 | 48 | 11.0 ± 3.0 | 29 (60.4) | Poland | 54 weeks | 4.5 ± 2.3 | 4.1 ± 2.0 | 5.6 ± 1.7 | 5.6 ± 1.5 | eGFR |
| Wenping et al. (2019) | 2019 | 68 | 37.0 ± 11.0 | 41 (60.3) | China | 24 weeks | NA | NA | NA | NA | Scr, eGFR |
| Jing et al. (2020) | 2020 | 61 | 47.5 ± 10.3 | 24 (39.3) | China | 4 weeks | 3.4 ± 1.3 | 4.0 ± 1.4 | NA | NA | Scr |
| Hugo et al. (2021) | 2021 | 183 | 51.2 ± 12.7 | 112 (61.2) | Germany | 48 weeks | NA | NA | 6.8 ± 2.0 | 5.6 ± 1.3 | eGFR |
| Xiaohong et al. (2021) | 2021 | 83 | 43.2 ± 10.9 | 57 (68.7) | China | 144 weeks | 2.1 ± 0.8 | 2.1 ± 0.8 | 7.2 ± 2.8 | 6.1 ± 2.1 | Scr and eGFR |
| Chenguang et al. (2021) | 2021 | 22 | 10.6 ± NA | 14 (63.6) | China | 48 weeks | 3.8 ± 2.3 | 4.0 ± 2.4 | 6.2 ± 0.9 | 7.3 ± 1.7 | Scr |
| Ziyu et al. (2022) | 2022 | 39 | NA | NA | China | 48 weeks | NA | NA | 7.1 ± 3.1 | 6.9 ± 1.7 | Scr |
| Haiwei et al. (2022) | 2022 | 101 | 41.9 ± 10.4 | 62 (61.4) | China | 20 weeks | 3.3 ± 1.3 | 4.5 ± 1.9 | 6.4 ± 2.3 | 6.8 ± 1.7 | Scr |
SD, standard deviation; NA, not accessible.